Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 7/20 | 0.49 |
| ▸ | BCR | P11274 | 6/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403039 | 0.88 | ABL1 (0.56) | DHODHABL1BCRTTBK1TTBK2 | |
| SCHEMBL3402884 | 0.86 | ABL1 (0.51) | DHODHABL1BCREPHX2TTBK1 | |
| SCHEMBL18696393 | 0.86 | ABL1 (0.53) | DHODHABL1BCRF9TTBK1 | |
| SCHEMBL3400784 | 0.85 | TP53 (0.56) | ABL1BCRTRPV1FAAHEPHX2 | |
| SCHEMBL23637017 | 0.83 | ABL1 (0.48) | DHODHABL1BCRTRPV1TTBK1 | |
| SCHEMBL18696183 | 0.83 | ABL1 (0.51) | ABL1BCRF9TTBK1TTBK2 | |
| SCHEMBL17487035 | 0.83 | ABL1 (0.50) | DHODHABL1BCRF9TTBK1 | |
| SCHEMBL12943130 | 0.83 | ABL1 (0.57) | DHODHABL1BCRTTBK1TTBK2 | |
| SCHEMBL3402905 | 0.83 | ABL1 (0.55) | ABL1BCRTRPV1KDR | |
| SCHEMBL3401859 | 0.83 | ABL1 (0.52) | DHODHABL1BCRTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | US | disclosed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| EP-2222162-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | DHODH 2768/4885ABL1 2/4885BCR 1/4885 |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | DHODH 1668/4885ABL1 2/4885BCR 1/4885 |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | DHODH 2778/4885ABL1 2/4885BCR 1/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | DHODH 2778/4885ABL1 2/4885BCR 1/4885 |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | DHODH 2667/4885ABL1 2/4885BCR 1/4885 |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | DHODH 3194/4885ABL1 2/4885BCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.